

15th June, 2020

BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
-------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sirs,

Sub: Disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading Regulation), 2015

We are enclosing herewith disclosure received from Designated Person of the Company under Regulation 7(2) of the SEBI (Prohibition of Insider Trading Regulations), 2015.

Kindly take the same on your records and acknowledge the receipt.

Thanking you,

For **Wockhardt Limited**



Gajanand Sahu
Company Secretary

Encl : As above



FORM C

**SEBI (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7(2) read with Regulation 6 (2) – Continual disclosure]**

Name of the Company : Wockhardt Limited
ISIN of the Company : INE049B01025

Details of change in holding of Securities of Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2)

Name, PAN, CIN/ DIN & Address with contact nos.	Category of person (Promoter/m ember of the promoter group/design ated person/ Director s/immediate relative to/others etc.)	Securities held prior to acquisition/disposal		Securities acquired/ Disposed				Securities held post acquisition/ disposal		Date of allotment advice/ acquisition of shares/- sale of shares specify		Date of intimati on to compa ny	Mode of acquisition/ Disposal (on market / public rights/ preferential offer/ off market/ inter se transfer, ESOPs etc.)	Exchange on which the trade was executed
		Type of security (for e.g. - Shares Warrants, Convertible Debentures, Rights entitlements etc.)	No. and % of Shareholding	Type of securities (For eg. Shares, Warrants, Convertible Debentures, Rights Entitlement, etc.)	No.	Value (Rs.)	Transaction Type (Purchase/sale Pledge / Revocation / Invocation/ Others please specify)	Type of securities (For eg. - Shares, Warrants, Convertible Debentures, Rights Entitlement, etc.)	No. and % of sharehol ding	From	To			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Name: Mahesh Patel PAN: AAGPP8538C Address: N-3, CIDCO, Aurangabad. Contact No: 9823068956	Others	Equity Shares	No: 81,760 Share- holding: 0.074%	Equity Shares	20,000	13143500.58	Sale	Equity Shares	No: 61,760 Share- holding: 0.056%	10/06/2021	11/06/2021	14/06/2021	Sale	NSE

Note (1) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI(Prohibition of Insider Trading) Regulations, 2015.
(2) Value of transaction excludes taxes/brokerage/any other charges

Details of trading in derivatives of the Company by Promoter, Employee or Director of a listed Company and other such persons as mentioned in Regulation 6(2)

Trading in derivatives (Specify type of contract, Futures or Options etc.)						Exchange on which the trade was executed
Type of Contract	Contract specifications	Buy		Sell		
		Notional Value	Number of units (contracts *lot size)	Notional Value	Number of units (contracts *lot size)	
15	16	17	18	19	20	21
-	-	-	-	-	-	N.A.

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

Maresh M.V.

Name & Signature : Dr. Mahesh Patel
Designation : Chief Scientific Officer – Drug Discovery
Date : 14/06/2021
Place : Aurangabad

FORM C

**SEBI (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7(2) read with Regulation 6 (2) – Continual disclosure]**

Name of the Company : Wockhardt Limited
ISIN of the Company : INE049B01025

Details of change in holding of Securities of Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2)

Name, PAN, CIN/ DIN & Address with contact nos.	Category of person (Promoter/m ember of the promoter group/desig nated person/ Director s/immediate relative to/others etc.)	Securities held prior to acquisition/disposal		Securities acquired/ Disposed				Securities held post acquisition/ disposal		Date of allotment advice/ acquisition of shares/ sale of shares specify		Date of intimati on to compa ny	Mode of acquisition/ Disposal (on market / public rights/ preferential offer/ off market/ inter se transfer, ESOPs etc.)	Exchange on which the trade was executed
		Type of security (for e.g. - Shares Warrants, Convertible Debentures, Rights entitlements etc.)	No. and % of Shareholding	Type of securities (For eg. Shares, Warrants, Convertible Debentures, Rights Entitlement, etc.)	No.	Value (Rs.)	Transaction Type (Purchase/sale Pledge / Revocation / Invocation/ Others please specify)	Type of securities (For eg. – Shares, Warrants, Convertible Debentures, Rights Entitlement, etc.)	No. and % of sharehol ding	From	To			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Name: Mahesh Patel PAN: AAGPP8538C Address: N-3, CIDCO, Aurangabad. Contact No: 9823068956	Others	Equity Shares	No: 61,760 Share- holding: 0.056%	Equity Shares	10,000	6609002.80	Sale	Equity Shares	No: 51,760 Share- holding: 0.047%	14/06/2021	14/06/2021	14/06/2021	Sale	NSE

Note (1) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI(Prohibition of Insider Trading) Regulations, 2015.
(2) Value of transaction excludes taxes/brokerage/any other charges

Details of trading in derivatives of the Company by Promoter, Employee or Director of a listed Company and other such persons as mentioned in Regulation 6(2)

Trading in derivatives (Specify type of contract, Futures or Options etc.)						Exchange on which the trade was executed
Type of Contract	Contract specifications	Buy		Sell		
		Notional Value	Number of units (contracts *lot size)	Notional Value	Number of units (contracts *lot size)	
15	16	17	18	19	20	21
-	-	-	-	-	-	N.A.

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.



Name & Signature : Dr. Mahesh Patel
Designation : Chief Scientific Officer – Drug Discovery
Date : 14/06/2021
Place : Aurangabad